The pharmaceutical community is excited with anticipation surrounding retatrutide, retatrutide effect on kidneys a new dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for treating obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a greater substantial decrease in body weigh